Empagliflozin: Side Effects, Uses & Monitoring
JARDIANCE is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- Data source
- FDA labeling via NIH DailyMed (label 5777b8a8…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
JARDIANCE is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. • to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. • to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Tests providers may use to monitor Empagliflozin therapy
Conditions associated with Empagliflozin in labeling
Chronic Kidney Disease
Progressive loss of kidney function over time, often caused by diabetes and hypertension, leading to buildup o...
Heart Failure
A condition in which the heart cannot pump blood effectively, leading to fluid buildup in the lungs and body a...
Type 2 Diabetes
A chronic condition in which the body becomes resistant to insulin or does not produce enough insulin to maint...
Frequently Asked Questions
What is Empagliflozin used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Empagliflozin?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Empagliflozin require lab monitoring?
Labeling and standard practice associate Empagliflozin with periodic laboratory monitoring; the tests above are commonly ordered by clinicians to monitor patients on therapy. Your provider decides what is appropriate.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.